| Literature DB >> 34837968 |
Kosei Yamaguchi1,2, Mineaki Kitamura3,4, Takahiro Takazono5,6, Shuntaro Sato7, Kazuko Yamamoto5,6, Satoko Notomi2, Kenji Sawase2, Takashi Harada2, Satoshi Funakoshi2, Hiroshi Mukae6,8, Tomoya Nishino1.
Abstract
BACKGROUND: Although muscle mass loss and pneumonia are common and crucial issues in hemodialysis (HD) patients, few reports have focused on their association, which remains unclear. This study assessed the association between skeletal muscle mass and the incidence of pneumonia in HD patients using the psoas muscle index (PMI).Entities:
Keywords: Hemodialysis; Muscle mass loss; Pneumonia; Psoas muscle index
Mesh:
Year: 2021 PMID: 34837968 PMCID: PMC8627609 DOI: 10.1186/s12882-021-02612-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Patient flowchart
Fig. 2Measurement of psoas muscle area on the birth month’s CT scan. a. CT image showing the lower border of the third lumbar vertebra. b. The cross-sectional area of the bilateral psoas muscle was measured (manual trace method)
Fig. 3Cumulative incidence of pneumonia requiring hospitalization during the observation period
Fig. 4Distribution of the psoas muscle index according to sex
Baseline patient characteristics
| Q1 | Q2 | Q3 | Q4 | ||
|---|---|---|---|---|---|
| Observation perioda (days) | 1091 (425–3287) | 1596 (862.5–3203) | 1479 (723–3303) | 2698 (1361–3446) | < 0.001 |
| Age (years) | 73.6 ± 11.2 | 69.4 ± 12.5 | 67.3 ± 12.4 | 58.7 ± 12.7 | < 0.001 |
| Female (%) | 69.9 | 53.7 | 33.7 | 15.9 | < 0.001 |
| Duration of dialysisa (months) | 45 (14–108) | 55 (22–118) | 68 (23–124) | 75 (31–147) | 0.11 |
| Dialysis timea (h) | 3 (3–4) | 4 (3–4) | 4 (3–4) | 4 (3–4) | < 0.001 |
| Kt/V | 1.4 ± 0.5 | 1.4 ± 0.4 | 1.3 ± 0.3 | 1.3 ± 0.3 | 0.16 |
| Ischemic heart disease (%) | 33.7 | 39.0 | 33.7 | 26.8 | 0.43 |
| Diabetes mellitus (%) | 26.5 | 36.6 | 37.3 | 36.6 | 0.40 |
| Cerebral hemorrhage (%) | 3.6 | 9.8 | 3.6 | 8.5 | 0.23 |
| Cerebral infarction (%) | 25.3 | 24.4 | 26.5 | 17.1 | 0.48 |
| Arteriosclerosis obliterans (%) | 16.9 | 20.7 | 15.7 | 12.2 | 0.53 |
| Cardiothoracic ratio (%) | 54.8 ± 6.45 | 52.9 ± 4.9 | 50.7 ± 5.2 | 50 ± 4.8 | < 0.001 |
| Body weight (kg) | 45.3 ± 7.6 | 49.9 ± 9.6 | 53.4 ± 9.7 | 60.2 ± 11.0 | < 0.001 |
| Body mass index (kg/m2) | 18.9 ± 2.4 | 20.4 ± 2.8 | 21.1 ± 2.9 | 23.0 ± 3.7 | < 0.001 |
| Systolic blood pressure (mmHg) | 147 ± 27 | 151 ± 24 | 147 ± 24 | 153 ± 23 | 0.17 |
| Diastolic blood pressure (mmHg) | 72 ± 11 | 77 ± 13 | 80 ± 14 | 83 ± 14 | < 0.001 |
| Left ventricular ejection fraction (%) | 65 ± 11 | 65 ± 10 | 64 ± 9.7 | 66 ± 9.7 | 0.50 |
| White blood cell (/μL) | 5437 ± 2170 | 6047 ± 932 | 5264 ± 1912 | 4078 ± 1186 | 0.15 |
| Hemoglobin (g/dL) | 10.5 ± 1.5 | 10.8 ± 1.3 | 11.0 ± 1.3 | 11.0 ± 1.3 | 0.072 |
| Ferritina (ng/mL) | 62 (23–209) | 59 (25.7–109) | 45 (20–142) | 57 (17–186) | 0.89 |
| TSAT (%) | 23 ± 14 | 24 ± 11 | 24 ± 13 | 27 ± 14 | 0.42 |
| Albumin (g/dL) | 3.4 ± 0.4 | 3.6 ± 0.4 | 3.6 ± 0.4 | 3.8 ± 0.3 | < 0.001 |
| cCa (mg/dL) | 9.2 ± 0.6 | 9.3 ± 0.8 | 9.2 ± 0.8 | 9.3 ± 0.7 | 0.38 |
| P (mg/dL) | 5.2 ± 1.3 | 5.4 ± 1.5 | 5.8 ± 1.5 | 6.1 ± 1.9 | 0.001 |
| Intact-PTHa (pg/mL) | 61 (23–113) | 54 (23–135) | 80 (30–171) | 112 (47–203) | 0.004 |
| ALPa (IU/L) | 255 (205–348) | 260 (187–333) | 266 (192–369) | 221 (179–308) | 0.057 |
| BUN (mg/dL) | 64 ± 20 | 68 ± 17 | 70 ± 17 | 71 ± 17 | 0.035 |
| Creatinine (mg/dL) | 8.3 ± 3.0 | 9.4 ± 2.9 | 11.0 ± 3.3 | 12.6 ± 3.0 | < 0.001 |
| Total cholesterol (mg/dL) | 158 ± 36 | 166 ± 36 | 165 ± 3.6 | 157 ± 31 | 0.51 |
| Triglyceridesa (mg/dL) | 84 (65–121) | 90 (63–117) | 92 (70–133) | 100 (65–147) | 0.36 |
| CRPa (mg/dL) | 0.23 (0.09–1.1) | 0.16 (0.06–0.60) | 0.14 (0.07–0.45) | 0.18 (0.07–0.49) | 0.13 |
| Anti-platelet drugs (%) | 39 | 41 | 41 | 34 | 0.76 |
| Warfarin (%) | 7.2 | 7.3 | 7.2 | 7.4 | 1.00 |
| ESAa (IU/week) | 7500 (2000–10,000) | 4500 (2000–9000) | 4000 (2000–8000) | 4000 (938–8000) | 0.091 |
| Iron (%) | 25.3 | 14.6 | 20.5 | 17.1 | 0.34 |
| Calcium carbonate (%) | 32.5 | 47.6 | 56.6 | 54.9 | < 0.001 |
| Lanthanum carbonate (%) | 19.3 | 35.4 | 27.7 | 45.1 | 0.003 |
| Sevelamer (%) | 1.2 | 2.5 | 3.6 | 4.9 | 0.55 |
| Cinacalcet (%) | 10.8 | 16.1 | 15.7 | 24.7 | 0.12 |
| Vitamin D (%) | 56.6 | 70.4 | 66.3 | 76.0 | 0.062 |
| GNRI | 85.8 ± 7.3 | 90.7 ± 7.3 | 92.3 ± 7.5 | 95.8 ± 6.4 | < 0.001 |
| NRI a | 8 (4–11) | 5 (3–8) | 4 (0–7) | 3 (0–4) | < 0.001 |
| Pneumonia (%) | 26 | 37 | 19 | 13 | 0.001 |
One Way Analysis of variance and The Kruskal-Wallis Analysis of Variance were used to compare continuous variables. The Kruskal-Wallis Analysis of Variance on Ranks was used to compare the categorical variables. TSAT transferrin saturation, cCa corrected calcium, P phosphate, ALP alkaline phosphatase, BUN blood urea nitrogen, CRP C-reactive protein, ESA erythropoiesis-stimulating agents, BMI body mass index, GNRI geriatric nutritional risk index, NRI nutritional risk index for hemodialysis patients, PMI psoas muscle mass index. a median (interquartile range)
Competing-Risk Cox regression analysis of the risk of pneumonia requiring hospitalization
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||
| Age /year | 1.03 | 1.01 to 1.06 | 0.017 | 1.03 | 1.00 to 1.05 | 0.027 | 1.04 | 1.02 to 1.07 | 0.017 | 1.04 | 1.01 to 1.07 | 0.004 |
| Female vs male | 0.68 | 0.38 to 1.16 | 0.15 | 0.66 | 0.38 to 1.12 | 0.12 | 0.77 | 0.46 to 1.31 | 0.34 | 0.76 | 0.45 to 1.30 | 0.32 |
| Dialysis vintage /year | 1.00 | 0.97 to 1.04 | 0.72 | 1.00 | 1.97 to 1.04 | 0.95 | 1.00 | 0.96 to 1.04 | 0.97 | 1.00 | 0.96 to 1.04 | 0.97 |
| DM history | 1.17 | 0.68 to 2.02 | 0.57 | 1.23 | 0.71 to 2.14 | 0.46 | 1.18 | 0.69 to 2.02 | 0.55 | 1.20 | 0.70 to 2.01 | 0.50 |
| Stroke history | 1.80 | 1.02 to 3.21 | 0.044 | 1.89 | 1.08 to 3.32 | 0.026 | 1.88 | 1.05 to 3.35 | 0.033 | 1.86 | 1.05 to 3.31 | 0.035 |
| Creatinine /SD | 0.78 | 0.56 to 1.10 | 0.16 | – | – | – | – | – | – | – | – | – |
| PMI /SD | – | – | – | 0.67 | 0.47 to 0.95 | 0.025 | – | – | – | – | – | – |
| GNRI /SD | – | – | – | – | – | – | 1.04 | 0.80 to 1.35 | 0.75 | – | – | – |
| NRI /SD | – | – | – | – | – | – | – | – | – | 1.10 | 0.84 to 1.45 | 0.48 |
The increase in the hazard ratio for one-unit change in the continuous variable. Model 1: adjusted for serum albumin and creatinine, Model 2: adjusted for the psoas muscle index, Model 3: adjusted for the geriatric nutritional risk index, and Model 4: adjusted for the psoas muscle mass index
HR hazard ratio, 95% CI 95% confidence interval, DM diabetes mellitus, SD standard deviation, PMI psoas muscle mass index, GNRI geriatric nutritional risk index, NRI nutritional risk index for hemodialysis patients
Fig. 5Associations between PMI and pneumonia development
Relationship between the psoas muscle index and serum creatinine levels
| The psoas muscle index | |||
|---|---|---|---|
| β | 95% CI | ||
| Creatinine (mg/dL) | 0.274 | 30.0 to 30.9 | < 0.001 |
| r2 | 0.244 | ||
95% CI, 95% confidence interval